Background <p>Biliary tract cancer (BTC) is an aggressive malignancy with limited treatment options and a poor prognosis. Although immune checkpoint inhibitors combined with chemotherapy have improved patient outcomes, their toxicity remains concerning. This phase II multicenter trial evaluated the efficacy and safety of pembrolizumab plus lenvatinib with a reduced-dose gemcitabine and oxaliplatin (GEMOX) regimen as a first-line therapy for advanced…
Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study
Journal for ImmunoTherapy of Cancer | | Piao, M., Li, C., Li, S., Zhang, N., Li, J., Luo, X., Liu, R., Wang, F., Shi, X., Liu, C., Tan, G., Zhu, Z., Yang, X., Zhao, H.
Topics: immunotherapy, chemotherapy, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer